» Authors » David J Bond

David J Bond

Explore the profile of David J Bond including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 69
Citations 2097
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Miley K, Hooker S, Crain A, OConnor P, Haapala J, Bond D, et al.
Gen Hosp Psychiatry . 2024 Mar; 85:139-147. PMID: 38487652
Objective: To estimate 30-year CVD risk and modifiable risk factors in young adults with serious mental illness (SMI) versus those without, and assess variations in CVD risk by race, ethnicity,...
2.
Nunez N, Coombes B, Beaupre L, Ozerdem A, Resendez M, Romo-Nava F, et al.
Transl Psychiatry . 2024 Feb; 14(1):93. PMID: 38351009
There is increasing interest in individualizing treatment selection for more than 25 regulatory approved treatments for major depressive disorder (MDD). Despite an inconclusive efficacy evidence base, antidepressants (ADs) are prescribed...
3.
Yatham L, Arumugham S, Kesavan M, Ramachandran K, Murthy N, Saraf G, et al.
N Engl J Med . 2023 Aug; 389(5):430-440. PMID: 37530824
Background: Antidepressants are used to treat acute depression in patients with bipolar I disorder, but their effect as maintenance treatment after the remission of depression has not been well studied....
4.
Miley K, Meyer-Kalos P, Ma S, Bond D, Kummerfeld E, Vinogradov S
Psychol Med . 2023 Jun; 53(5):2041-2049. PMID: 37310333
Background: We aimed to identify unmet treatment needs for improving social and occupational functioning in early schizophrenia using a data-driven causal discovery analysis. Methods: Demographic, clinical, and psychosocial measures were...
5.
Bond D, Andreazza A, Torres I, Honer W, Lam R, Yatham L
J Affect Disord . 2022 Sep; 319:229-234. PMID: 36155232
Background: We previously reported that in early-stage bipolar disorder (BD), frontal and temporal lobe volume reductions were more pronounced in patients with elevated BMI and more rapidly progressive in patients...
6.
von Mucke Similon M, Paasche C, Krol F, Lerer B, Goodwin G, Berk M, et al.
Eur Neuropsychopharmacol . 2022 Jun; 60:91-99. PMID: 35665655
The use of randomized clinical trials, in particular placebo-controlled trials, for drug approval, is the subject of long-standing debate in the scientific community and beyond. This study offers consensus recommendations...
7.
Gardea-Resendez M, Winham S, Romo-Nava F, Cuellar-Barboza A, Clark M, Andreazza A, et al.
J Affect Disord . 2022 May; 310:150-155. PMID: 35545158
Objectives: Recognizing bipolar disorder as a multi-system metabolic condition driven, in part, by binge eating behavior and atypical depressive symptoms, this study aimed to quantify diet quality and evaluate clinical...
8.
Nunez N, Coombes B, Romo-Nava F, Bond D, Vande Voort J, Croarkin P, et al.
Front Psychiatry . 2022 May; 13:884217. PMID: 35492709
Background: Bipolar disorder (BD) with co-occurring attention deficit-hyperactivity disorder (ADHD) is associated with an unfavorable course of illness. We aimed to identify potential clinical and genetic correlates of BD with...
9.
Taylor-Desir M, Balls-Berry J, McElroy S, Bond D, Vallender E, Ladner M, et al.
J Racial Ethn Health Disparities . 2022 Jan; 10(1):367-372. PMID: 35064520
Aim: This study quantified and compared demographic and clinical features of bipolar disorder (BD) in persons of African ancestry (AA) and European ancestry (EUR). Methods: Participants enrolled in the Mayo...
10.
Yatham L, Chakrabarty T, Bond D, Schaffer A, Beaulieu S, Parikh S, et al.
Bipolar Disord . 2021 Oct; 23(8):767-788. PMID: 34599629
Objectives: The 2018 Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) guidelines provided clinicians with pragmatic treatment recommendations for bipolar disorder (BD). While...